NCT02839798终止2 期
Evaluation of NeoSync EEG Synchronized TMS For the Treatment of Major Depressive Episode in Bipolar Disorder and Associated Neural Response: An Open Label Trial
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 6
- 试验地点
- 2
- 主要终点
- Mean MADRS Total Score Change (Last Observation Carried Forward)
研究概览
简要总结
This study is designed to evaluate the safety and preliminary efficacy of synchronized transcranial magnetic stimulation (sTMS) using the NeoSync EEG Synchronized TMS device (NEST) in subjects with Bipolar Disorder type I in a Major Depressive Episode. This is an open label study in which subjects will receive treatment 5 days per week for 6 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must meet all of the following inclusion criteria to qualify for enrollment into the study:
- •18 - 70 years of age;
- •DSM-5 primary diagnosis of Bipolar Disorder type 1 (with a documented past manic episode), currently in a Major Depressive Episode by diagnostic criteria elicited by structured clinical interview (SCID-5-RV);
- •MADRS score ≥ 20;
- •Duration of current episode >4 weeks
- •YMRS score ≤ 12;
- •baseline EEG of sufficient quality for quantitative analysis processing;
- •willing and able to adhere to the intensive treatment schedule and all required study visits;
- •currently on adequate dose of mood stabilizer with significant evidence base or FDA approval as antimanic or for maintenance therapy of bipolar disorder (e.g, valproic acid/divalproex, carbamazepine, lithium, aripiprazole, ziprasidone, risperidone, quetiapine, olanzapine, asenapine, haloperidol, chlorpromazine, paliperidone, cariprazine).
排除标准
- •Subjects will be excluded from study participation if one of the following exclusion criteria applies:
- •unable or unwilling to give informed consent;
- •diagnosed with current primary psychotic disorder (rather than BD);
- •diagnosed with current mania or hypomanic mood episode;
- •history of moderate to severe substance use disorder within the past 6 months (except nicotine and caffeine);
- •currently being treated with a stimulant;
- •clinically defined major neurological disorder; including, but not limited to, seizure disorder and history of loss of consciousness due to head injury for greater than 10 minutes, or with documented evidence of brain injury;
- •increased risk of seizure for any reason, including diagnosis of increased intracranial pressure, comorbid neurological disorder, use of certain medications, highly unstable use of alcohol or benzodiazepines;
- •initiation of new antidepressant treatments (new medication, new device-based stimulation, or new psychotherapy) within 6 weeks prior to study baseline;
- •active suicidal intent or plan as detected on screening assessments, or in the Investigator's opinion, is likely to attempt suicide within the next six months;
- •presence of implanted cardiac pacemakers, implanted medication pumps, or intracardiac lines;
- •intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, stents, or electrodes) or any other metal object within or near the head (excluding the mouth), which cannot be safely removed;
- •clinically significant unstable medical condition;
- •if female: pregnant, not using medically acceptable means of birth control, or currently breastfeeding;
- •other condition, which in the judgment of the Investigator could prevent the subject from completion of the study;
- •for participants in the MRI study: ferromagnetic metal implant or other contraindication to imaging in a 3 Tesla MRI;
- •past treatment with TMS therapy.
结局指标
主要结局
Mean MADRS Total Score Change (Last Observation Carried Forward)
时间窗: Baseline to week 6 reported
The Montgomery-Asberg Depression Rating Scale (MADRS) will be performed as a baseline and endpoint assessments and efficacy measure. It's considered the gold standard for rating depression severity and used frequently in clinical trials. The MADRS score ranges from 0 to 60; a score of 0-6 is generally accepted to be within the normal range (or in clinical remission), while a score of 20 or higher indicates at least moderate severity.
次要结局
- Mean HDRS-17 Total Score Change (Last Observation Carried Forward)(Baseline and week 6)
- Mean IDS-SR Score Change (Last Observation Carried Forward)(Baseline through week 6)
研究者
Linda L Carpenter MD
Chief, Mood Disorder Research Program
Butler Hospital
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive DisorderMajor Depressive DisorderNCT01370733Wave Neuroscience202
已完成
不适用
Brain-oscillation Synchronised Stimulation of the Prefrontal CortexDepressionNCT02920840University Hospital Tuebingen17
招募中
不适用
Brain-Oscillation-Synchronized Stimulation to Enhance Motor Recovery in Early Subacute StrokeIschemic Stroke, AcuteNCT05600374University Hospital Tuebingen144
撤回
不适用
TMS-EEG for Cortical ExcitabilityAcquired Brain InjuryTraumatic Brain InjuryStrokeHealthyNCT05472363Mayo Clinic
撤回
不适用
Safety and Efficacy of Synchronized Transcranial Magnetic Stimulation for the Treatment of Generalized Anxiety DisorderGeneralized Anxiety Disorder (GAD)NCT02708472University of Texas Southwestern Medical Center